Denali-Sanofi scraps mid-stage study for multiple sclerosis drug

Denali Therapeutics

10/10/2024 21:14

Oct 10 (Reuters) - Drug developer Denali Therapeutics
 DNLI.O  said on Thursday its partner Sanofi  SASY.PA  has
discontinued a mid-stage study testing their experimental drug
to treat multiple sclerosis as it failed to meet the main and
secondary goals.     

 (Reporting by Mariam Sunny in Bengaluru; Editing by Alan
Barona)
 ((Mariam.ESunny@thomsonreuters.com))